Platinum containing regimens for metastatic breast cancer
Author:
Publisher
John Wiley & Sons, Ltd
Link
https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003374.pub3/epdf/full
Reference32 articles.
1. Time to progression in metastatic breast cancer patients treated with epirubicin is not improved by the addition of either cisplatin or lonidamine: final results of a phase III study with a factorial design;Berruti;J Clin Oncol
2. Time to progression in metastatic breast cancer patients treated with epirubicin is not improved by the addition of either cisplatin or lonidamine: final results of a phase III study with a factorial design;Berruti;J Clin Oncol
3. Cisplatin and etoposide as first-line chemotherapy for metastatic breast carcinoma: a prospective randomized trial of the Italian Oncology Group for Clinical Research;Cocconi;J Clin Oncol,1991
4. Comparison of CMF (cyclophosphamide, methotrexate, and 5-fluorouracil) with a rotational crossing and a sequential intensification regimen in advanced breast cancer: a prospective randomized study;Cocconi;Am J Clin Oncol,1999
5. Continuous CMF compared to a short chemotherapy using cisplatin-containing combinations in metastatic breast carcinoma. A prospective randomized study;Cocconi;Ann Oncol,1996
Cited by 25 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Platinum-containing regimens for triple-negative metastatic breast cancer;Cochrane Database of Systematic Reviews;2020-10-21
2. Outcomes of systemic therapy for advanced triple-negative breast cancer: A single centre experience;The Breast;2018-08
3. First-line paclitaxel and cisplatin used sequentially or in combination in metastatic breast cancer: A phase II randomized study;Journal of the Egyptian National Cancer Institute;2018-03
4. Platinum-containing regimens for metastatic breast cancer;Cochrane Database of Systematic Reviews;2017-06-23
5. Platinum salts in advanced breast cancer: a systematic review and meta-analysis of randomized clinical trials;Breast Cancer Research and Treatment;2016-10-21
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3